{"schema_version":"secwatch.filing_event.v1","accession":"0001965040-24-000019","form_type":"8-K","ticker":"FTRE","cik":"0001965040","company_name":"Fortrea Holdings Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.328939+00:00","generated_at":"2026-06-02T02:50:47.730286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortrea reports Q1 revenue $662.1M, net loss $81.6M; FY revenue guidance $2.785-2.855B","bullets":["Q1 revenue $662.1M vs $693.9M YoY; GAAP net loss $81.6M vs net income $7.3M YoY.","Adjusted EBITDA $29.5M vs $41.7M YoY; GAAP diluted EPS $(0.91), adjusted $(0.04).","Book-to-bill 1.11x; backlog $7.4B; free cash flow $(34.9)M.","Planned divestiture of Endpoint Clinical and Patient Access to Arsenal Capital on track for Q2 close.","FY 2024 guidance: revenue $2,785-2,855M, adjusted EBITDA $240-260M."],"urls":{"canonical":"https://secwatch.observer/filing/0001965040-24-000019","json":"https://secwatch.observer/filing/0001965040-24-000019.json","markdown":"https://secwatch.observer/filing/0001965040-24-000019.md","text":"https://secwatch.observer/filing/0001965040-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1965040/000196504024000019/0001965040-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1965040/000196504024000019/ftre-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:50:47.730286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b39a3be7d809e630374d59490de0fd1e8ab3ff9","claim":"Fortrea Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $662.1 million, net income GAAP net loss of $81.6 million, EPS $(0.91).","evidence_excerpt":"Fortrea Reports First Quarter 2024 Results For the three months ended March 31, 2024, from continuing operations: • Revenues of $662.1 million • GAAP net loss of $81.6 million • Adjusted EBITDA of $29.5 million • GAAP and adjusted diluted loss per share of $(0.91) and $(0.04), respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1965040/000196504024000019/0001965040-24-000019-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$662.1 million"},{"label":"Net income","value":"GAAP net loss of $81.6 million"},{"label":"EPS","value":"$(0.91)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}